DK2663313T3 - PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS - Google Patents

PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS Download PDF

Info

Publication number
DK2663313T3
DK2663313T3 DK12700137.8T DK12700137T DK2663313T3 DK 2663313 T3 DK2663313 T3 DK 2663313T3 DK 12700137 T DK12700137 T DK 12700137T DK 2663313 T3 DK2663313 T3 DK 2663313T3
Authority
DK
Denmark
Prior art keywords
treprostinil
cells
bone marrow
stem cells
prostacyclin
Prior art date
Application number
DK12700137.8T
Other languages
Danish (da)
English (en)
Inventor
Michael Freissmuth
Eva-Maria Zebedin-Brandl
Christian Bergmayr
Filza Hussain
Original Assignee
Scipharm S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2663313(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scipharm S A R L filed Critical Scipharm S A R L
Application granted granted Critical
Publication of DK2663313T3 publication Critical patent/DK2663313T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
DK12700137.8T 2011-01-13 2012-01-13 PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS DK2663313T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150835 2011-01-13
PCT/EP2012/050484 WO2012095511A1 (en) 2011-01-13 2012-01-13 Method for enhancing engraftment of haematopoetic stem cells

Publications (1)

Publication Number Publication Date
DK2663313T3 true DK2663313T3 (en) 2018-11-26

Family

ID=44146841

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12700137.8T DK2663313T3 (en) 2011-01-13 2012-01-13 PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS

Country Status (19)

Country Link
US (1) US10213464B2 (https=)
EP (1) EP2663313B1 (https=)
JP (2) JP6110309B2 (https=)
KR (1) KR101950526B1 (https=)
CN (1) CN103379907B (https=)
AU (1) AU2012206517B2 (https=)
BR (1) BR112013017878B1 (https=)
CA (1) CA2824113C (https=)
CL (1) CL2013002034A1 (https=)
DK (1) DK2663313T3 (https=)
EA (1) EA033717B1 (https=)
ES (1) ES2693622T3 (https=)
IL (1) IL227331A (https=)
PL (1) PL2663313T3 (https=)
PT (1) PT2663313T (https=)
SG (1) SG191908A1 (https=)
UA (1) UA113284C2 (https=)
WO (1) WO2012095511A1 (https=)
ZA (1) ZA201304743B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2879682B1 (en) * 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
AU2015217142B2 (en) * 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
CA2946747A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
US10226465B2 (en) * 2015-01-27 2019-03-12 Scipharm Sàrl Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
CN109727671B (zh) * 2018-12-28 2021-07-09 广东省心血管病研究所 一种鉴定造血干细胞移植术效果的信息分析系统及方法
WO2025172541A1 (en) 2024-02-15 2025-08-21 Aop Orphan Pharmaceuticals Gmbh New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US8696564B2 (en) 2004-07-09 2014-04-15 Cardiac Pacemakers, Inc. Implantable sensor with biocompatible coating for controlling or inhibiting tissue growth
US20070065414A1 (en) * 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
US8575175B2 (en) * 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
CN108379292A (zh) 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
RS53234B (sr) * 2009-08-07 2014-08-29 Scipharm Sàrl Kompozicija za lečenje cistične fibroze

Also Published As

Publication number Publication date
EP2663313A1 (en) 2013-11-20
JP2017046707A (ja) 2017-03-09
CN103379907B (zh) 2018-01-09
ES2693622T3 (es) 2018-12-13
JP2014507409A (ja) 2014-03-27
ZA201304743B (en) 2014-09-25
UA113284C2 (xx) 2017-01-10
NZ612450A (en) 2015-03-27
BR112013017878A8 (pt) 2018-01-09
US20130344038A1 (en) 2013-12-26
AU2012206517A1 (en) 2013-08-01
IL227331A0 (en) 2013-09-30
US10213464B2 (en) 2019-02-26
IL227331A (en) 2017-12-31
EA201300817A1 (ru) 2013-11-29
SG191908A1 (en) 2013-08-30
KR101950526B1 (ko) 2019-02-20
PT2663313T (pt) 2018-10-23
CL2013002034A1 (es) 2014-03-21
BR112013017878A2 (https=) 2017-08-15
CN103379907A (zh) 2013-10-30
JP6110309B2 (ja) 2017-04-05
KR20140005956A (ko) 2014-01-15
PL2663313T3 (pl) 2019-01-31
EP2663313B1 (en) 2018-08-08
EA033717B1 (ru) 2019-11-19
WO2012095511A1 (en) 2012-07-19
AU2012206517B2 (en) 2016-12-01
CA2824113A1 (en) 2012-07-19
BR112013017878B1 (pt) 2021-08-31
CA2824113C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
DK2663313T3 (en) PROCEDURE FOR IMPROVING ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
CA2973146C (en) Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
KR102143961B1 (ko) 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료
EP2408444A2 (en) Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
HK1186389A (en) Method for enhancing engraftment of haematopoetic stem cells
HK1186389B (en) Method for enhancing engraftment of haematopoetic stem cells
NZ612450B2 (en) Method for enhancing engraftment of haematopoetic stem cells
WO2025172541A1 (en) New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts
HK1241742B (en) Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation